57 ( 88 % ) of 65 patients in the intravenous rituximab safety population had adverse events ( 30 [ 46 % ] grade 3 ) , as did 57 ( 92 % ) of 62 patients in the subcutaneous rituximab safety population ( 29 [ 47 % ] grade 3 ) .